0 CHECKOUT

Benign Prostatic Hyperplasia - Pipeline Review, H1 2015

  • ID: 3293096
  • May 2015
  • 133 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AmVac AG
  • Aphios Corporation
  • Euroscreen S.A.
  • KAEL-GemVax Co., Ltd.
  • Neurocentrx Pharma Ltd.
  • MORE

Benign Prostatic Hyperplasia - Pipeline Review, H1 2015

Summary

This, ‘Benign Prostatic Hyperplasia - Pipeline Review, H1 2015’, provides an overview of the Benign Prostatic Hyperplasia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AmVac AG
  • Aphios Corporation
  • Euroscreen S.A.
  • KAEL-GemVax Co., Ltd.
  • Neurocentrx Pharma Ltd.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Benign Prostatic Hyperplasia Overview
Therapeutics Development
Pipeline Products for Benign Prostatic Hyperplasia - Overview
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes
Benign Prostatic Hyperplasia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Benign Prostatic Hyperplasia - Products under Development by Companies
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
AmVac AG
AndroScience Corporation
Aphios Corporation
Ausio Pharmaceuticals, LLC
Biolab Sanus Farmaceutica Ltda.
Chong Kun Dang Pharmaceutical Corp.
Corium International, Inc.
Curadis GmbH
Euroscreen S.A.
Hanmi Pharmaceuticals, Co. Ltd.
IntelGenx Corp.
Jeil Pharmaceutical Co., Ltd.
KAEL-GemVax Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Meiji Seika Pharma Co., Ltd.
Mezzion Pharma Co. Ltd.
Neurocentrx Pharma Ltd.
Nymox Pharmaceutical Corporation
Ono Pharmaceutical Co., Ltd.
Quest PharmaTech Inc.
SK Chemicals Co., Ltd.
SOM Innovation Biotech SL
Sophiris Bio, Inc.
Yungjin Pharm Ind. Co., Ltd.
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tamsulosin hydrochloride + dutasteride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-68692 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMV-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-JM.X2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CKD-902 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-1493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Burning Sensation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIP-1402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INT-0031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JLP-1207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-1AD3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCS-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NX-1207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-40542 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOM-2391 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOM-2393 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sperol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
talaporfin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tamsulosin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tamsulosin hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
topsalysin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YOB-1604 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benign Prostatic Hyperplasia - Recent Pipeline Updates
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Featured News & Press Releases
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2015
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Benign Prostatic Hyperplasia - Pipeline by AbbVie Inc., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H1 2015
Benign Prostatic Hyperplasia - Pipeline by AmVac AG, H1 2015
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H1 2015
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H1 2015
Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H1 2015
Benign Prostatic Hyperplasia - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Corium International, Inc., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H1 2015
Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by IntelGenx Corp., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by KAEL-GemVax Co., Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Neurocentrx Pharma Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H1 2015
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Quest PharmaTech Inc., H1 2015
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H1 2015
Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H1 2015
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H1 2015
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H1 2015
Benign Prostatic Hyperplasia - Dormant Projects, H1 2015
Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H1 2015
Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H1 2015
Benign Prostatic Hyperplasia - Dormant Projects (Contd..3), H1 2015
Benign Prostatic Hyperplasia - Discontinued Products, H1 2015
Benign Prostatic Hyperplasia - Discontinued Products (Contd..1), H1 2015

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2015
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AbbVie Inc.
Addex Therapeutics Ltd
AmVac AG
AndroScience Corporation
Aphios Corporation
Ausio Pharmaceuticals, LLC
Biolab Sanus Farmaceutica Ltda.
Chong Kun Dang Pharmaceutical Corp.
Corium International, Inc.
Curadis GmbH
Euroscreen S.A.
Hanmi Pharmaceuticals, Co. Ltd.
IntelGenx Corp.
Jeil Pharmaceutical Co., Ltd.
KAEL-GemVax Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Meiji Seika Pharma Co., Ltd.
Mezzion Pharma Co. Ltd.
Neurocentrx Pharma Ltd.
Nymox Pharmaceutical Corporation
Ono Pharmaceutical Co., Ltd.
Quest PharmaTech Inc.
SK Chemicals Co., Ltd.
SOM Innovation Biotech SL
Sophiris Bio, Inc.
Yungjin Pharm Ind. Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.